Evidence map›Paper›PMID 39421536›Full record

ArticleFrontiers in endocrinology2024

Case report: A novel

Suresh Chandran, Deepti Verma, Victor Samuel Rajadurai, Fabian Yap

Abstract readCase Reports
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Suresh ChandranDivision of Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Deepti VermaDivision of Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Victor Samuel RajaduraiDivision of Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Fabian YapDivision of Medicine, KK Women's and Children's Hospital, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diazoxide (DZX) remains the first-line medication for the treatment of prolonged and persistent forms of hyperinsulinemic hypoglycemia (HH). In nearly 40%-50% of cases of HH, the genetic mechanism is unidentified. Almost half of the infants with permanent or genetic causes are DZX sensitive, but hypersensitivity to DZX is extremely rare, and the mechanism is poorly understood. Here, we report for the first time a case of DZX hypersensitivity in a neonate with HH who inherited a novel

Indexed as

Congenital HyperinsulinismDiabetes, GestationalDiazoxideHepatocyte Nuclear Factor 1-alphaFemaleHumansInfant, NewbornMalePregnancyDiazoxideHepatocyte Nuclear Factor 1-alphaHNF1A protein, humancongenital hyperinsulinismdiazoxide hypersensitivitygestational diabetesHNF1A varianthypoglycemiainfant of diabetic mother

Identifiers

PMID39421536
PMCPMC11484256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.